Blue Water Life Science Advisors LP Takes $3.04 Million Position in Tempus AI, Inc. (NASDAQ:TEM)

Blue Water Life Science Advisors LP bought a new position in Tempus AI, Inc. (NASDAQ:TEM) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 90,000 shares of the company’s stock, valued at approximately $3,038,000. Tempus AI accounts for 2.7% of Blue Water Life Science Advisors LP’s investment portfolio, making the stock its 8th biggest holding. Blue Water Life Science Advisors LP owned approximately 0.06% of Tempus AI at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. ARK Investment Management LLC raised its holdings in shares of Tempus AI by 132.1% in the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after buying an additional 3,141,487 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 166.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after acquiring an additional 2,021,394 shares during the period. Nikko Asset Management Americas Inc. raised its stake in Tempus AI by 166.0% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after acquiring an additional 2,021,394 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Tempus AI by 240.5% during the fourth quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after acquiring an additional 1,950,862 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Tempus AI by 86,947.2% in the 4th quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company’s stock valued at $55,836,000 after purchasing an additional 1,651,996 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

TEM has been the subject of a number of recent analyst reports. William Blair reiterated a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Bank of America raised their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Wolfe Research downgraded Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Loop Capital dropped their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Finally, Morgan Stanley lifted their price objective on Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $61.18.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $40.42 on Friday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The business has a 50-day moving average price of $54.10 and a two-hundred day moving average price of $50.60.

Insider Transactions at Tempus AI

In other news, EVP Andrew Polovin sold 13,135 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total value of $603,947.30. Following the transaction, the executive vice president now directly owns 154,171 shares in the company, valued at $7,088,782.58. This trade represents a 7.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $49.84, for a total value of $23,734,256.56. Following the completion of the sale, the chief executive officer now owns 6,502,643 shares of the company’s stock, valued at $324,091,727.12. This represents a 6.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,146,249 shares of company stock worth $301,185,058 in the last quarter.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.